Taken together, deregulation of the PI3K/Akt/mTOR pathway is frequently detected in GBM (in around 88%) [12] and has been found to contribute to a variety of cellular responses, thus rendering this pathway and especially the PI3Ks interesting candidates for targeted therapies. The gene discussed is PIK3CB; the disease is glioblastoma.